Rallybio Corporation

AI Score

0

Unlock

0.85
0.01 (0.68%)
At close: Feb 10, 2025, 10:56 AM
undefined
undefined%
After-hours undefined
undefined%
Bid 0.85
Market Cap 35.26M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.57
PE Ratio (ttm) -0.54
Forward PE n/a
Analyst Buy
Ask 0.86
Volume 43,844
Avg. Volume (20D) 81,715
Open 0.85
Previous Close 0.84
Day's Range 0.83 - 0.90
52-Week Range 0.82 - 3.46
Beta undefined

About RLYB

Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclona...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 29, 2021
Employees 43
Stock Exchange NASDAQ
Ticker Symbol RLYB

Analyst Forecast

According to 5 analyst ratings, the average rating for RLYB stock is "Buy." The 12-month stock price forecast is $9.5, which is an increase of 1017.65% from the latest price.

Buy 80.00%
Hold 20.00%
Sell 0.00%
Stock Forecasts
10 months ago
-26.17%
Rallybio shares are trading lower as the stock pul... Unlock content with Pro Subscription
10 months ago
+82.82%
Rallybio shares are trading higher after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT.